Drug-resistant TB is an AMR emergency

Mel Spigelman

President and CEO, TB Alliance

Drug-resistant tuberculosis (TB) is a major part of the AMR crisis. Treatment has come a long way, but shorter, safer options could help cure more patients while decreasing the burden on healthcare systems.


When we talk about antimicrobial resistance (AMR), one of the biggest pieces of the picture is often left out. TB is the world’s deadliest infectious disease, and drug-resistant TB is a major cause of deaths related to AMR. In 2024, an estimated 390,000 people developed drug-resistant TB and 150,000 people died from it.1

Costs of drug-resistant TB

Unlike many other leading AMR threats, drug-resistant TB is airborne; it can pass from person to person. Delayed diagnosis and gaps in effective treatment give the disease more opportunities to spread. The cost is measured in lives, as well as in the strain on families, economies and entire health systems. Estimates of single-year economic losses from preventable deaths due to drug-resistant TB approach $50 billion.2

Continued scientific progress and sustained investment can put within reach an end to drug-resistant TB

Progress worth protecting

New, all-oral regimens can treat many people with drug-resistant TB in six months,3 replacing treatments that often lasted 18 months or longer and often required taking 14,000+ pills over the course of treatment.3 Further progress can make treatment more manageable and help more people complete it.

These six-month regimens are a major advance, but stopping drug-resistant TB and confronting AMR will take even shorter and simpler treatments. It will also take advances in treating latent TB and drug-sensitive TB to stem the reservoirs of future cases.

An AMR agenda that includes TB

Continued scientific progress and sustained investment can put within reach an end to drug-resistant TB. We need rapid tests that identify active and latent TB along with drug resistance, reliable access to the best available treatments and support that helps healthcare systems provide adequate care.

With funding for TB services under pressure, the pursuit of this mission is being challenged, but we can’t retreat now. Tackling AMR means investing in both the tools people need today and the next generation of treatments. For TB, that commitment could prevent transmission, preserve effective medicines, save lives and revitalise economies.

[1] World Health Organization. Global tuberculosis report 2025. Geneva: World Health Organization; 2025.
[2] Silva S, Arinaminpathy N, Atun R et al. Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis. The Lancet Global Health; 2021; 9, e1372-e1379
[3] Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline–pretomanid–linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022;387(9):810–823. [1] Gupta A, Juneja S, Sahu S, et al. Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis. PLOS Glob Public Health. 2022;2(11):e0001287.

More from AMR & Infectious Diseases